Key Points
- Wendy Becker purchased 4,000 GSK shares on April 29 at GBX 1,963 (≈£78,520) and had made earlier purchases of 411 shares (Mar 20) and 3,334 shares (Feb 20), indicating repeated insider buying.
- GSK beat Q1 expectations with GBX 46.50 EPS and GBX 762.9bn revenue—HIV and oncology sales offset weakness in other medicines—and its chronic hepatitis B candidate secured an FDA priority review with an October decision window.
- The stock has a consensus analyst rating of Hold with an average target around GBX 2,055.7, and trades with a market capitalization of about £76.7bn and a P/E near 13.8.
GSK plc (LON:GSK - Get Free Report) insider Wendy Becker acquired 4,000 shares of the stock in a transaction on Wednesday, April 29th. The stock was bought at an average price of GBX 1,963 per share, with a total value of £78,520.
Wendy Becker also recently made the following trade(s):
- On Friday, March 20th, Wendy Becker bought 411 shares of GSK stock. The stock was bought at an average cost of GBX 1,963 per share, with a total value of £8,067.93.
- On Friday, February 20th, Wendy Becker bought 3,334 shares of GSK stock. The shares were bought at an average price of GBX 2,219 per share, for a total transaction of £73,981.46.
GSK Price Performance
GSK opened at GBX 1,918 on Thursday. The company has a debt-to-equity ratio of 108.20, a current ratio of 0.82 and a quick ratio of 0.73. The stock has a market capitalization of £76.66 billion, a P/E ratio of 13.82, a price-to-earnings-growth ratio of 1.24 and a beta of 0.35. The company's 50 day simple moving average is GBX 2,090.52 and its 200-day simple moving average is GBX 1,923.32. GSK plc has a one year low of GBX 1,288.61 and a one year high of GBX 2,282.
GSK (LON:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. The firm had revenue of GBX 762.90 billion during the quarter. Sell-side analysts anticipate that GSK plc will post 175.980975 earnings per share for the current fiscal year.
Key Headlines Impacting GSK
Here are the key news stories impacting GSK this week:
- Positive Sentiment: Insider buying: A senior insider, Wendy Becker, purchased 4,000 GSK shares at GBX 1,963, signaling management confidence in the shares. Insider Purchase Report
- Positive Sentiment: Q1 results beat: GSK reported GBX 46.50 EPS and GBX 762.9bn revenue; HIV and oncology products helped offset weakness in other medicines, supporting near-term earnings. Q1 Beat Coverage
- Positive Sentiment: Regulatory progress: GSK’s chronic hepatitis B candidate secured FDA priority review and management is targeting an October decision, which could be a material upside if approved. FDA Priority Review
- Positive Sentiment: Commercial momentum: Company commentary and coverage highlight first-quarter sales strength under new CEO Luke Miels, which investors may view as early validation of the turnaround plan. CEO Commentary
- Neutral Sentiment: Analyst stance: Deutsche Bank reaffirmed a "hold" rating with a GBX 1,900 target — suggests muted near-term upside per a major broker. Broker Note
- Neutral Sentiment: Marketing initiatives: GSK launched a shingles awareness campaign in Singapore — supportive for long-term brand/market penetration but not material to near-term earnings. Campaign
- Negative Sentiment: Legal provisions and litigation worries: Coverage notes legal provisions and a pre-trial setback for Tesaro (Jemperli dispute), which clouds near-term cash flow and creates headline risk. Legal Provisions Coverage
- Negative Sentiment: R&D/priorities cut: GSK walked away from a $100M option on Mersana’s STING ADC and paused its mRNA bird-flu program — these moves reduce near-term R&D optionality and may worry growth-focused investors. Program Pause Report
- Negative Sentiment: Business mix pressure: Commentary highlights that declines in older, general medicines are undermining GSK’s overhaul — a reminder that top-line mix shifts could keep margins and growth under pressure. Overhaul Concerns
- Negative Sentiment: Tesaro legal setback: A pre-trial blow in the Jemperli contract dispute with AnaptysBio raises potential litigation costs/uncertainty tied to the Tesaro unit. Tesaro Litigation
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on GSK shares. UBS Group reiterated a "neutral" rating and issued a GBX 1,940 price target on shares of GSK in a report on Friday, January 23rd. Berenberg Bank restated a "hold" rating and set a GBX 2,000 target price on shares of GSK in a research report on Thursday, March 26th. Jefferies Financial Group reaffirmed a "buy" rating and issued a GBX 2,500 target price on shares of GSK in a research note on Tuesday, April 14th. Shore Capital Group reiterated a "buy" rating on shares of GSK in a research report on Wednesday, March 25th. Finally, JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a research note on Wednesday, January 7th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of GBX 2,055.71.
Read Our Latest Report on GSK
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
